In Embryos, Crispr Can Cut Out Whole Chromosomes—That's Bad
By Megan Molteni,
Wired
| 10. 29. 2020
The DNA-cutting tool has been hailed as a way to fix genetic glitches. But a new study suggests it can remove more than scientists bargained for.
IN 2017, RESEARCHERS at Oregon Health and Science University came out with some big (if true) news. Led by a reproductive biologist named Shoukhrat Mitalipov, the scientists had used the Nobel Prize–winning molecular tool known as Crispr to fix a heart-condition-causing mutation in human embryos—a first in the US. A week later, the journal Nature published details of these boundary-pushing experiments. Up until that point, viable embryos had only been Crispr’d once before, in China. As WIRED reported at the time, Mitalipov’s team’s editing appeared to work surprisingly well. But one thing didn’t go as expected.
Crispr works by cleaving DNA apart at a specific location in the genome. Then it’s the cell’s job to repair the resulting double-stranded break. One way to make sure it does it right is to supply a bit of corrective DNA along with the Crispr components. But Mitalipov’s group reported that their embryos didn’t use the template they provided. The embryos had been created by fusing a healthy donor’s egg with a sperm that carried the mutation. But it turned...
Related Articles
By Maggie Astor, The New York Times | 06.23.2026
Every year, patients undergo millions of in vitro fertilization procedures worldwide. Only a minority result in a live birth.
In an effort to improve the odds, scientists have developed an array of “add-ons” that could in theory identify the most...
By Carl Zimmer and Catrin Einhorn, The New York Times | 06.25.2026
The Trump administration and a company that is promising to bring long-gone animals back from extinction announced a partnership on Thursday to preserve cells, tissue and DNA from threatened and endangered species.
The company, Colossal Biosciences, said its goal was...
By Marisa Flook , BioNews | 06.29.2026
An anti-ageing gene therapy not approved by the US Food and Drug Administration (FDA) is set to be offered by an American company at overseas clinics outside of US jurisdiction.
The treatment, developed by Minicircle from Austin, Texas, uses a...
By Philip Ball , Nature | 06.17.2026
Our genomes are full of mutations that have the potential to damage our health or even kill us. Yet most of them rarely cause problems. Why? It’s partly thanks to a family of proteins that mask, or ‘buffer’, the ill...